Lexaria Bioscience (LEXX) Receivables - Net (2010 - 2026)
Lexaria Bioscience's Receivables - Net was $113,012 in fiscal Q3 2026 (quarter ended May 31, 2026), down 73.2% from $422,143 a year earlier but up 6.6% from the prior quarter.
Powered by 
Analysis
Lexaria Bioscience (LEXX) Receivables - Net (2010 - 2026) Analysis & Trends
At the end of FY2025 (ended Aug 31, 2025), Receivables - Net at Lexaria Bioscience came in at $432,371, up 98.3% from FY2024.
- Receivables - Net shows a five-year compound annual growth rate of 6.6% (FY2020 to FY2025).
- In earlier fiscal years, Receivables - Net was $218,052 in FY2024 (+24.4%), $175,245 in FY2023 (-13.2%), $201,784 in FY2022 (-41.1%) and $342,401 in FY2021 (+9.1%).
- Quarterly Receivables - Net has moved between $106,043 (fiscal Q2 2026) and $534,731 (fiscal Q1 2024) over five years.
- Compared with a year earlier, Receivables - Net has declined for three straight quarters, with an average decline of 0.4% over the last eight quarters.
- The best year-over-year quarter for Receivables - Net over five years was fiscal Q2 2024 (growth of 161.0%); the worst was fiscal Q3 2022 (a decline of 83.8%).
- Per Business Quant data, LEXX's Receivables - Net in the three fiscal quarters before Q3 2026 was $106,043 (Q2 2026), $152,057 (Q1 2026) and $432,371 (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,170.46 Bn | 1,139.04 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 648.38 Bn | 568.24 Bn | 17.30 Bn |
| 3 | AbbVie | 504.43 Bn | 477.54 Bn | 12.70 Bn |
| 4 | Merck | 367.73 Bn | 322.11 Bn | 12.21 Bn |
| 5 | Novartis Ag | 303.35 Bn | 267.34 Bn | 11.24 Bn |
| 6 | Astrazeneca | 268.20 Bn | 241.88 Bn | 12.86 Bn |
| 7 | Amgen | 242.55 Bn | 197.95 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 194.80 Bn | 169.00 Bn | 6.22 Bn |
| 9 | Pfizer | 173.31 Bn | 119.95 Bn | 10.94 Bn |
| 10 | Lexaria Bioscience | 2.61 Mn | -12.65 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2026 | 113,012.00 |
| Feb 28, 2026 | 106,043.00 |
| Nov 30, 2025 | 152,057.00 |
| Aug 31, 2025 | 432,371.00 |
| May 31, 2025 | 422,143.00 |
| Feb 28, 2025 | 395,180.00 |
| Nov 30, 2024 | 327,505.00 |
| Aug 31, 2024 | 218,052.00 |
| May 31, 2024 | 208,445.00 |
| Feb 29, 2024 | 357,090.00 |
| Nov 30, 2023 | 534,731.00 |
| Aug 31, 2023 | 175,245.00 |
| May 31, 2023 | 172,284.00 |
| Feb 28, 2023 | 136,796.00 |
| Nov 30, 2022 | 286,322.00 |
| Aug 31, 2022 | 201,784.00 |
| May 31, 2022 | 154,868.00 |
| Feb 28, 2022 | 506,622.00 |
| Nov 30, 2021 | 461,512.00 |
| Aug 31, 2021 | 342,401.00 |
API Access
Lexaria Bioscience Receivables - Net API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=receivables-net&ticker=LEXX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "receivables-net", "ticker": "LEXX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=receivables-net&ticker=LEXX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();